Pharmaniaga's revenue soars but profits tumble in volatile 2025 fiscal year
Pharmaniaga Bhd saw mixed financial results for its 2025 fiscal year. While revenue climbed to RM3.92 billion, net profit dropped sharply to RM48.51 million. The company's shares remained highly active in trading view on 24 February 2026, reflecting investor interest despite the earnings dip.
The pharmaceutical firm reported a revenue increase of RM170 million compared to FY2024, reaching RM3.92 billion. However, net profit fell significantly, declining from RM131.82 million in the previous year to RM48.51 million. This contrast between higher sales and lower profitability drew attention from market watchers.
On 24 February 2026, Pharmaniaga's shares were among the most traded on Bursa Malaysia. By 11.40 am, the stock price stood at 30.5 sen, with 48.17 million shares changing hands. The trading view volume highlighted ongoing investor engagement despite the profit decline.
The company also improved its sustainability performance, with its FTSE4Good score rising to 4.6 in 2025. This increase underscored Pharmaniaga's stronger commitment to environmental, social, and governance (ESG) practices.
Looking ahead, MBSB Investment Bank Bhd forecast a better performance for FY2026. The bank cited government support and growing demand for insulin and vaccines as key drivers. MBSB maintained a 'buy' recommendation on the stock, raising its target price from 29 sen to 36 sen. Pharmaniaga's projected taxes budget for 2026 stands at RM2.1 billion, further supporting expectations of recovery.
Pharmaniaga's FY2025 results showed a revenue rise but a sharp profit decline. Analysts remain optimistic about its future, backed by government contracts and increasing demand for essential medicines. The company's improved ESG score and active trading view suggest continued market confidence.
